Get your patient on Foundayo (Orforglipron)

—
of the top 10 commercial plans cover Foundayo
—
of plans require PA
Compare GLP-1 Alternatives
See how Foundayo stacks up on access, cost, and PA burden — the factors that affect whether your patient can actually get on therapy.
Access MetricFoundayoOrforglipronzepboundmounjarowegovyozempic
Plan Coverage% of commercial plans—
PA Required% of plans requiring PA—
Copay w/ SavingsWith manufacturer card
Not available
Savings ProgramsTotal availableNot available
Approved IndicationsFDA-approved uses
Type 2 Diabetes
Get better comparisons with Prescriber.AI
See which alternative has the best coverage, lowest PA burden, and best savings for your patient's specific insurance.
See all comparisons →

Insurance Coverage

See specific coverage requirements for your patient's insurance plan.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
UnitedHealthcare (UHC)Foundayo
Covered on 4 commercial plans
PA (0/4) · Step therapy (0/4) · Qty limit (0/4)
View full coverage details
Aetna HealthFoundayo
Covered on 5 commercial plans
PA (0/5) · Step therapy (0/5) · Qty limit (0/5)
View full coverage details
CIGNAFoundayo
Covered on 4 commercial plans
PA (0/4) · Step therapy (0/4) · Qty limit (0/4)
View full coverage details
Coverage data sourced from MMIT. Updated monthly.

Savings & Copay Programs

Help your patients reduce out-of-pocket costs for Foundayo.

Prior Authorization7 forms
Download the right PA form for your patient's insurance plan.

Most recent Foundayo prior authorization forms

Aetna - Louisiania Prior Authorization Request FormUpdated Apr 24, 2026
Aetna - Medical Exception/Prior Authorization/Precertification Request for Prescription MedicationsUpdated Apr 24, 2026
Humana - General Prior Authorization FormUpdated Apr 24, 2026
Independence Health - Select Formulary Prior Authorization Form Updated Apr 24, 2026
Kaiser Permanente of Colorado - Medicare Medication Request form (MRF)Colorado · Updated Apr 24, 2026
View all PA forms for Foundayo
Brand Resources
Prior Authorization Resource Guide (US-OFG-2695)Comprehensive guide for HCPs submitting PA requests. Includes ICD-10 codes, BMI documentation, lifestyle modification requirements, and reauthorization tips.Updated Apr 06, 2026
Letter of Medical Necessity Template Guide (US-OFG-2696)Template and considerations for composing LON for PA appeals. Includes sample letters, required patient information, clinical rationale guidance, and plan submission requirements.Updated Apr 06, 2026
Prescribing Information
Indications
  • FOUNDAYO TM is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition.
  • Limitations of Use
  • Concomitant use with another GLP-1 receptor agonist is not recommended.
Dosing Titration
0.8
0.8 mgFirst 4 weeksTitration
2.5
2.5 mg≥4 weeks laterEscalation
5.5
5.5 mg≥4 weeks laterEscalation
9
9 mg≥4 weeks laterEscalation
14.5
14.5 mg≥4 weeks laterEscalation
17.2
17.2 mg≥4 weeks laterMax dose
Common Side Effects
Nausea
35%
Diarrhea
25%
Constipation
24%
Vomiting
24%
Abdominal pain
14%
Contraindications
  • A personal or family history of MTC or in patients with MEN 2.
  • Known serious hypersensitivity to orforglipron or any of the excipients in FOUNDAYO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with GLP-1 receptor agonists.
Full FDA Prescribing Information
Access the complete FDA-approved prescribing label for Foundayo, including approved indications, recommended dosage & administration schedules, contraindications, warnings & precautions, adverse reactions, drug interactions, and use in specific populations.

Resources

Dosage & administration

DOSAGE AND ADMINISTRATION

  • Take FOUNDAYO orally once daily, with or without food. (2.1 )
  • Swallow tablets whole. Do not break, crush, or chew. (2.1 )
  • Do not take more than one tablet per day. (2.1 )
  • Starting dosage is 0.8 mg once daily. After at least 30 days, increase dosage to 2.5 mg once daily. (2.1 )
  • After at least 30 days on the 2.5 mg dosage, increase dosage to 5.5 mg once daily. (2.1 )
  • Dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability. (2.1 )
  • Maximum dosage is 17.2 mg once daily. (2.1 )

Recommended Dosage and Administration

Recommended Administration

  • Take FOUNDAYO orally once daily, with or without food.
  • Swallow tablets whole. Do not break, crush, or chew.
  • Do not take more than one tablet per day.

Recommended Dosage Escalation

Follow the FOUNDAYO starting dosage and escalation described below to reduce the risk of gastrointestinal (GI) adverse reactions [see Warnings and Precautions (5.3 ), Adverse Reactions (6 )] .

  • The starting dosage is 0.8 mg orally once daily. After at least 30 days on the 0.8 mg dosage, increase the dosage to 2.5 mg once daily.
  • After at least 30 days on the 2.5 mg dosage, increase the dosage to 5.5 mg once daily.
  • The dosage may be increased to the next dosage level (9 mg, 14.5 mg, or 17.2 mg once daily) after at least 30 days on the current dosage, based on treatment response and tolerability.
  • The maximum dosage of FOUNDAYO is 17.2 mg once daily.

Dosage Modification for Concomitant Use with CYP3A4 Inhibitors and CYP3A4 Inducers

FOUNDAYO dosage modification may be required to manage interactions with some concomitant medications [see Drug Interactions (7.1 ), Clinical Pharmacology (12.3 )] .

Strong CYP3A4 Inhibitors

  • Avoid strong CYP3A4 inhibitors that also inhibit OATP1B when taking FOUNDAYO.
  • The maximum dosage of FOUNDAYO is 9 mg once daily when used concomitantly with a strong CYP3A4 inhibitor [see Drug Interactions (7.1 ), Clinical Pharmacology (12.3 )] .

Strong and Moderate CYP3A4 Inducers

  • Avoid strong CYP3A4 inducers when taking FOUNDAYO.
  • Monitor FOUNDAYO effectiveness when concomitantly using moderate CYP3A4 inducers and escalate FOUNDAYO dosage as needed [see Dosage and Administration (2.1 , 2.3 ), Drug Interactions (7.1 ), Clinical Pharmacology (12.3 )] .

Recommendations Regarding Missed Dose

  • If a dose is missed, instruct patients to take the dose as soon as possible.
  • Advise patients not to double up the next dose.
  • If 7 or more consecutive doses are missed, reinitiate dosage escalation at a lower dosage to reduce the risk of gastrointestinal adverse reactions [see Dosage and Administration (2.1 ), Warnings and Precautions (5.3 ), Adverse Reactions (6 )] .

PubMed™ news

    Show the latest PubMed™ articles for Foundayo

    Frequently Asked Questions